Tandem Diabetes Care
TNDM
247 hedge funds and large institutions have $1.65B invested in Tandem Diabetes Care in 2023 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 88 increasing their positions, 89 reducing their positions, and 62 closing their positions.
1% less repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 89
1.55% less ownership
Funds ownership: 105.49% → 103.94% (-1.5%)
10% less funds holding
Funds holding: 273 → 247 (-26)
34% less call options, than puts
Call options by funds: $4.58M | Put options by funds: $6.95M
40% less capital invested
Capital invested by funds: $2.77B → $1.65B (-$1.12B)
42% less first-time investments, than exits
New positions opened: 36 | Existing positions closed: 62
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PIM
Paradice Investment Management
Denver,
Colorado
|
+$39.5M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$25.4M |
| 3 |
Millennium Management
New York
|
+$24.2M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$21.1M |
| 5 |
EC
Eminence Capital
New York
|
+$20.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$118M |
| 2 |
CIP
Champlain Investment Partners
Burlington,
Vermont
|
-$53.2M |
| 3 |
BCM
Brown Capital Management
Baltimore,
Maryland
|
-$18.6M |
| 4 |
Morgan Stanley
New York
|
-$17M |
| 5 |
TLP
Tri Locum Partners
New York
|
-$17M |
TNDM Hedge Fund Activity: Q2 2023 in Review
247 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Tandem Diabetes Care (TNDM) for Q2 2023, worth a combined $1.65B — down 40% from $2.77B a quarter earlier.
Sellers outnumbered buyers: 62 funds closed out of TNDM and 36 opened new positions — a net loss of 26 holders — while 89 trimmed existing stakes and 88 added.
The largest buyer was Paradice Investment Management, opening a new position worth an estimated $39.5M. The largest seller was Fidelity Investments, cutting an estimated $118M.
- 247 institutional investors held Tandem Diabetes Care (TNDM) as of Q2 2023, down from 273 in Q1 2023.
- Funds reported $1.65B of Tandem Diabetes Care stock for Q2 2023, down 40% quarter-over-quarter.
- 36 funds opened new Tandem Diabetes Care positions in Q2 2023 and 62 closed out, a net change of -26 holders.
- The largest Tandem Diabetes Care buyer in Q2 2023 was Paradice Investment Management, an estimated $39.5M added.
- The largest Tandem Diabetes Care seller in Q2 2023 was Fidelity Investments, an estimated $118M sold.
Based on aggregated 13F filings for Q2 2023.